183 related articles for article (PubMed ID: 14504207)
21. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
Nogal A; Coelho A; Catarino R; Morais A; Lobo F; Medeiros R
Cancer Genet Cytogenet; 2007 Sep; 177(2):149-52. PubMed ID: 17854673
[TBL] [Abstract][Full Text] [Related]
22. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
[TBL] [Abstract][Full Text] [Related]
23. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
24. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
[TBL] [Abstract][Full Text] [Related]
25. Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.
He XF; Liu ZZ; Xie JJ; Wang W; Du YP; Chen Y; Wei W
Tumour Biol; 2014 Oct; 35(10):9859-77. PubMed ID: 24989928
[TBL] [Abstract][Full Text] [Related]
26. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.
Miao J; Jin Y; Marunde RL; Gorski CJ; Kim S; Quinney S; Radovich M; Li L; Hall SD
Pharmacogenomics J; 2009 Oct; 9(5):319-26. PubMed ID: 19506580
[TBL] [Abstract][Full Text] [Related]
27. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
[TBL] [Abstract][Full Text] [Related]
28. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
29. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans.
Sinues B; Vicente J; Fanlo A; Vasquez P; Medina JC; Mayayo E; Conde B; Arenaz I; Martinez-Jarreta B
Ther Drug Monit; 2007 Aug; 29(4):412-6. PubMed ID: 17667794
[TBL] [Abstract][Full Text] [Related]
30. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
[TBL] [Abstract][Full Text] [Related]
31. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.
Fukushima-Uesaka H; Saito Y; Watanabe H; Shiseki K; Saeki M; Nakamura T; Kurose K; Sai K; Komamura K; Ueno K; Kamakura S; Kitakaze M; Hanai S; Nakajima T; Matsumoto K; Saito H; Goto Y; Kimura H; Katoh M; Sugai K; Minami N; Shirao K; Tamura T; Yamamoto N; Minami H; Ohtsu A; Yoshida T; Saijo N; Kitamura Y; Kamatani N; Ozawa S; Sawada J
Hum Mutat; 2004 Jan; 23(1):100. PubMed ID: 14695543
[TBL] [Abstract][Full Text] [Related]
32. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
[TBL] [Abstract][Full Text] [Related]
33. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
Blanco JG; Edick MJ; Hancock ML; Winick NJ; Dervieux T; Amylon MD; Bash RO; Behm FG; Camitta BM; Pui CH; Raimondi SC; Relling MV
Pharmacogenetics; 2002 Nov; 12(8):605-11. PubMed ID: 12439220
[TBL] [Abstract][Full Text] [Related]
35. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VM; Jones BC; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2006 Sep; 16(9):637-45. PubMed ID: 16906018
[TBL] [Abstract][Full Text] [Related]
36. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
37. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
Novillo A; Romero-Lorca A; Gaibar M; Bahri R; Harich N; Sánchez-Cuenca D; Esteban E; Fernández-Santander A
Int J Biol Markers; 2015 Feb; 30(1):e148-51. PubMed ID: 25385241
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.
Eap CB; Buclin T; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
Eur J Clin Pharmacol; 2004 Jun; 60(4):231-6. PubMed ID: 15114431
[TBL] [Abstract][Full Text] [Related]
40. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
Br J Cancer; 2003 Mar; 88(6):928-32. PubMed ID: 12644831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
